Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor–positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials
Titel:
Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor–positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials
Auteur:
Martín, M. Loibl, S. Hyslop, T. De la Haba-Rodríguez, J. Aktas, B. Cirrincione, C.T. Mehta, K. Barry, W.T. Morales, S. Carey, L.A. Garcia-Saenz, J.A. Partridge, A. Martinez-Jañez, N. Hahn, O. Winer, E. Guerrero-Zotano, A. Hudis, C. Casas, M. Rodriguez-Martin, C. Furlanetto, J. Carrasco, E. Dickler, M.N.